NeuroPace, Inc. (NASDAQ:NPCE) Receives $15.50 Average PT from Brokerages

Shares of NeuroPace, Inc. (NASDAQ:NPCE - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the six research firms that are presently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $15.50.

A number of brokerages recently weighed in on NPCE. HC Wainwright started coverage on shares of NeuroPace in a research report on Wednesday, May 28th. They set a "buy" rating and a $18.00 price objective for the company. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $17.00 target price on shares of NeuroPace in a report on Wednesday, May 14th. Finally, JPMorgan Chase & Co. raised their price target on NeuroPace from $14.00 to $16.00 and gave the stock an "overweight" rating in a report on Wednesday, May 14th.

Insider Activity

In other news, major shareholder Orbimed Advisors Llc sold 168,136 shares of the stock in a transaction on Wednesday, May 14th. The stock was sold at an average price of $15.85, for a total value of $2,664,955.60. Following the completion of the transaction, the insider now owns 3,238,199 shares of the company's stock, valued at approximately $51,325,454.15. This represents a 4.94% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Corporate insiders own 20.50% of the company's stock.

Institutional Investors Weigh In On NeuroPace

Several institutional investors have recently bought and sold shares of NPCE. BNP Paribas Financial Markets bought a new stake in shares of NeuroPace during the 4th quarter worth about $29,000. GAMMA Investing LLC bought a new stake in NeuroPace during the first quarter worth approximately $53,000. Wells Fargo & Company MN raised its holdings in NeuroPace by 54.2% during the fourth quarter. Wells Fargo & Company MN now owns 6,483 shares of the company's stock worth $73,000 after purchasing an additional 2,279 shares in the last quarter. MetLife Investment Management LLC acquired a new stake in NeuroPace in the fourth quarter worth approximately $103,000. Finally, Birchview Capital LP bought a new position in NeuroPace during the 4th quarter valued at $112,000. Institutional investors and hedge funds own 78.83% of the company's stock.

NeuroPace Price Performance

NASDAQ NPCE traded down $0.19 on Friday, hitting $10.57. 405,321 shares of the stock traded hands, compared to its average volume of 175,346. The company has a current ratio of 6.63, a quick ratio of 5.70 and a debt-to-equity ratio of 2.46. The stock has a 50-day moving average of $12.83 and a 200 day moving average of $12.37. NeuroPace has a twelve month low of $5.45 and a twelve month high of $18.98.

NeuroPace (NASDAQ:NPCE - Get Free Report) last released its quarterly earnings data on Tuesday, May 13th. The company reported ($0.21) EPS for the quarter, topping analysts' consensus estimates of ($0.26) by $0.05. NeuroPace had a negative net margin of 29.42% and a negative return on equity of 190.84%. The firm had revenue of $22.52 million during the quarter, compared to the consensus estimate of $21.85 million. Equities research analysts expect that NeuroPace will post -1 EPS for the current year.

NeuroPace Company Profile

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.